Dicerna will present "The Translation of DsiRNA-EX Conjugate Delivery in Mouse Models to Non-Human Primate Models." The presentation will be available after the presentation event on Dicerna's website in the events & presentation section at www.dicerna.com.
Dicerna is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company is using its proprietary RNA interference technology platform to build a broad pipeline in these therapeutic areas. In both rare diseases and oncology, Dicerna is pursuing targets that have historically been difficult to inhibit using conventional approaches, but where connections between targets and diseases are well understood and documented. The Company intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, please visit www.dicerna.com.
News Provided by Acquire Media